Header Logo

Connection

David Smelson to Treatment Outcome

This is a "connection" page, showing publications David Smelson has written about Treatment Outcome.
Connection Strength

0.458
  1. Corrigan PW, Qin S, Davidson L, Schomerus G, Shuman V, Smelson D. How does the public understand recovery from severe mental illness versus substance use disorder? Psychiatr Rehabil J. 2019 Dec; 42(4):341-349.
    View in: PubMed
    Score: 0.073
  2. Smelson DA, Chinman M, Hannah G, Byrne T, McCarthy S. An evidence-based co-occurring disorder intervention in VA homeless programs: outcomes from a hybrid III trial. BMC Health Serv Res. 2018 May 05; 18(1):332.
    View in: PubMed
    Score: 0.067
  3. Blonigen DM, Cucciare MA, Timko C, Smith JS, Harnish A, Kemp L, Rosenthal J, Smelson D. Study protocol: a hybrid effectiveness-implementation trial of Moral Reconation Therapy in the US Veterans Health Administration. BMC Health Serv Res. 2018 03 07; 18(1):164.
    View in: PubMed
    Score: 0.066
  4. Smelson DA, Zaykowski H, Guevermont N, Siegfriedt J, Sawh L, Modzelewski D, Tsemberis S, Kane V. Integrating Permanent Supportive Housing and Co-Occurring Disorders Treatment for Individuals Who Are Homeless. J Dual Diagn. 2016 Apr-Jun; 12(2):193-201.
    View in: PubMed
    Score: 0.058
  5. Smelson DA, Kline A, Kuhn J, Rodrigues S, O'Connor K, Fisher W, Sawh L, Kane V. A wraparound treatment engagement intervention for homeless veterans with co-occurring disorders. Psychol Serv. 2013 May; 10(2):161-7.
    View in: PubMed
    Score: 0.046
  6. Smelson D, Chen KW, Ziedonis D, Andes K, Lennox A, Callahan L, Rodrigues S, Eisenberg D. A pilot study of Qigong for reducing cocaine craving early in recovery. J Altern Complement Med. 2013 Feb; 19(2):97-101.
    View in: PubMed
    Score: 0.045
  7. Smelson DA, Dixon L, Craig T, Remolina S, Batki SL, Niv N, Owen R. Pharmacological treatment of schizophrenia and co-occurring substance use disorders. CNS Drugs. 2008; 22(11):903-16.
    View in: PubMed
    Score: 0.033
  8. Smelson DA, Tunis SL, Nyhuis AW, Faries DE, Kinon BJ, Ascher-Svanum H. Antipsychotic treatment discontinuation among individuals with schizophrenia and co-occurring substance use. J Clin Psychopharmacol. 2006 Dec; 26(6):666-7.
    View in: PubMed
    Score: 0.030
  9. Smelson DA, Roy A, Roy M. Risperidone diminishes cue-elicited craving in withdrawn cocaine-dependent patients. Can J Psychiatry. 1997 Nov; 42(9):984.
    View in: PubMed
    Score: 0.016
  10. Rogers E, Fernandez S, Gillespie C, Smelson D, Hagedorn HJ, Elbel B, Kalman D, Axtmayer A, Kurowski K, Sherman SE. Telephone care coordination for smokers in VA mental health clinics: protocol for a hybrid type-2 effectiveness-implementation trial. Addict Sci Clin Pract. 2013 Mar 15; 8:7.
    View in: PubMed
    Score: 0.012
  11. Rosenheck R, Perlick D, Bingham S, Liu-Mares W, Collins J, Warren S, Leslie D, Allan E, Campbell EC, Caroff S, Corwin J, Davis L, Douyon R, Dunn L, Evans D, Frecska E, Grabowski J, Graeber D, Herz L, Kwon K, Lawson W, Mena F, Sheikh J, Smelson D, Smith-Gamble V. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA. 2003 Nov 26; 290(20):2693-702.
    View in: PubMed
    Score: 0.006
  12. Howanitz E, Pardo M, Smelson DA, Engelhart C, Eisenstein N, Stern RG, Losonczy MF. The efficacy and safety of clozapine versus chlorpromazine in geriatric schizophrenia. J Clin Psychiatry. 1999 Jan; 60(1):41-4.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.